Immunomedics to Report Results for the Fourth Quarter and Full Year 2019 and Host Conference Call and Webcast on February 27,...
February 20 2020 - 8:00AM
Immunomedics, Inc. (NASDAQ: IMMU)
(“Immunomedics” or the “Company”), a leading biopharmaceutical
company in the area of antibody-drug conjugates, today announced
that it will host a conference call on Thursday, February 27, 2020
at 5:00 p.m. Eastern Time to discuss financial results for the
fourth quarter and full year 2019 and provide a corporate update.
To access the conference call, please dial (877)
303-2523 or (253) 237-1755 using the Conference ID 4365097. The
conference call will be webcast via the Investors page on the
Company’s website at https://immunomedics.com/investors/.
Approximately two hours following the live event, a webcast replay
of the conference call will be available on the Company’s website
for approximately 30 days.
About Immunomedics
Immunomedics is a clinical-stage
biopharmaceutical company developing monoclonal antibody-based
products for the targeted treatment of cancer. Immunomedics’
corporate objective is to become a fully-integrated
biopharmaceutical company and a leader in the field of
antibody-drug conjugates. For additional information on the
Company, please visit its website at https://immunomedics.com/. The
information on its website does not, however, form a part of this
press release.
Cautionary note regarding forward-looking
statements
This release, in addition to historical
information, may contain forward-looking statements made pursuant
to the Private Securities Litigation Reform Act of 1995. Such
statements, including statements regarding expectations for the
outcome of our resubmission of our Biologics License Application
("BLA") for sacituzumab govitecan for the treatment of patients
with metastatic triple-negative breast cancer ("mTNBC") who have
received at least two prior therapies for metastatic disease; the
United States Food and Drug Administration ("FDA") re-inspection of
the Company’s manufacturing facility where we manufacture the
monoclonal antibody for further manufacture into our
antibody-drug-conjugate candidate sacituzumab govitecan; potential
approval and commercial launch of sacituzumab govitecan for that
indication and the Company’s development of sacituzumab govitecan
for additional indications; clinical trials (including the funding
therefor, anticipated patient enrollment, trial outcomes, timing or
associated costs); regulatory applications and related timelines,
including the filing and approval timelines for BLAs, BLA
resubmissions, and BLA supplements; out-licensing arrangements;
forecasts of future operating results, potential collaborations,
capital raising activities, and the timing for bringing any product
candidate to market; our inability to further identify, develop and
achieve commercial success for new products and technologies; the
possibility of delays in the research and development necessary to
select drug development candidates and delays in clinical trials;
the risk that clinical trials may not result in marketable
products; the risk that we may be unable to obtain additional
capital through strategic collaborations, licensing, convertible
debt securities or equity financing in order to continue our
research and development programs as well as secure regulatory
approval of and market our drug candidates; our dependence upon
pharmaceutical and biotechnology collaborations; the levels and
timing of payments under our collaborative agreements;
uncertainties about our ability to obtain new corporate
collaborations and acquire new technologies on satisfactory terms,
if at all; the development of competing products; our ability to
protect our proprietary technologies; patent infringement claims;
and risks of new, changing and competitive technologies and
regulations in the United States and internationally, as well as
the risks discussed in the Company’s filings with the Securities
and Exchange Commission. The Company is not under any obligation,
and the Company expressly disclaims any obligation, to update or
alter any forward-looking statements, whether as a result of new
information, future events or otherwise.
For More Information:
Dr. Chau Cheng(862)
260-3727ccheng@immunomedics.com
For Media Inquiries:
Darren Opland, Ph.D.(646)
627-8387Darren@lifescipublicrelations.com
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Sep 2023 to Sep 2024